– UK, Worthing – Allergy Therapeutics plc (LON: AGY), the fully integrated specialty pharmaceutical group specializing in allergy vaccines, today announced the appointment of Cheryl MacDiarmid to its Board as a Non-Executive Director, with effect from 27 October 2021.
“We are delighted to welcome Cheryl to the Board of Allergy Therapeutics. Cheryl brings highly relevant experience, with her knowledge of the healthcare sector, expertise in marketing and commercial strategy, and her understanding of the US market, especially in the light of our recent announcement that our pivotal G306 Phase III trial is on track to commence in H2 2022 in US and Europe. I have no doubt she will be an important contributor to the Board.” said Board Chairman, Peter Jensen.
Cheryl MacDiarmid will also join the Audit Committee.
About Cheryl MacDiarmid
Cheryl MacDiarmid has more than 25 years of experience in commercial roles within the global pharmaceutical sector. She brings significant marketing, strategy, and management expertise, having worked for GlaxoSmithKline since 1993, where she has focussed mainly on the commercial aspects of the business, developing a deep knowledge of sales and marketing operations in North America. Cheryl has significant senior management experience within GSK, initially in Canada and then in the US where she led the Respiratory Business Unit and associated US operations. In 2019 Cheryl was appointed SVP and Head, Global Commercial Strategy for ViiV Healthcare, the joint venture between GSK, Pfizer, and Shionogi which specializes in the development of therapies for HIV.
Cheryl MacDiarmid commented: “I am delighted to be joining the Board of Allergy Therapeutics at an exciting time for the Company. I look forward to helping the Board to further strengthen Allergy’s leadership in the allergy immunotherapeutics field, providing innovative products to help people worldwide.”
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost the performance of vaccines outside allergy are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, the UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved 10% compound annual growth since its formation, employs c.500 employees and is listed on the London Stock Exchange (LON: AGY).
For more information: https://www.allergytherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
